Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld Sells 75 Shares

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 75 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $152.80, for a total value of $11,460.00. Following the completion of the transaction, the executive vice president directly owned 21,009 shares of the company’s stock, valued at approximately $3,210,175.20. This represents a 0.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Tuesday, May 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $147.35, for a total value of $11,051.25.
• On Monday, April 27th, Michael Feld sold 74 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $151.94, for a total value of $11,243.56.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX traded up $4.68 during mid-day trading on Friday, reaching $156.06. 12,180,552 shares of the company’s stock were exchanged, compared to its average volume of 2,402,854. The firm has a 50-day moving average price of $148.15 and a two-hundred day moving average price of $170.85. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. The firm has a market capitalization of $43.00 billion, a price-to-earnings ratio of 39.51, a price-to-earnings-growth ratio of 10.72 and a beta of 0.22. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. During the same quarter in the prior year, the business earned $3.35 earnings per share. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Analysts predict that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be paid a dividend of $1.05 per share. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 106.33%.

Wall Street Analyst Weigh In

BDX has been the subject of several research reports. Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Piper Sandler lowered their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Stifel Nicolaus dropped their price target on Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday, May 7th. Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a research note on Tuesday, April 14th. Finally, Argus lowered their price objective on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research note on Monday, March 23rd. Seven equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $181.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BDX. Crux Wealth Advisors lifted its position in shares of Becton, Dickinson and Company by 0.8% during the fourth quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier’s stock worth $1,222,000 after acquiring an additional 49 shares in the last quarter. Larson Financial Group LLC raised its stake in shares of Becton, Dickinson and Company by 1.7% during the 4th quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $627,000 after purchasing an additional 53 shares during the period. Camelot Portfolios LLC lifted its holdings in Becton, Dickinson and Company by 1.5% during the 4th quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock worth $688,000 after purchasing an additional 54 shares in the last quarter. McElhenny Sheffield Capital Management LLC boosted its stake in Becton, Dickinson and Company by 3.6% in the 4th quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier’s stock worth $309,000 after purchasing an additional 55 shares during the period. Finally, Atlantic Union Bankshares Corp boosted its stake in Becton, Dickinson and Company by 0.9% in the 4th quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock worth $1,185,000 after purchasing an additional 57 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.